Evidence map›Paper›PMID 31745340›Full record

ArticleNature immunology2019

TCR sequencing paired with massively parallel 3' RNA-seq reveals clonotypic T cell signatures.

Ang A Tu, Todd M Gierahn, Brinda Monian, Duncan M Morgan, Naveen K Mehta, Bert Ruiter, Wayne G Shreffler, Alex K Shalek, J Christopher Love

Abstract read
In one paragraph

Article in Nature immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. T Cell Thoughts.Immunological reviews · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Antigen-specific TScience advances · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Expansion of tumor-reactive CD8Science immunology · 2024
    Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Ang A Tu *Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5145-7869
Todd M Gierahn *Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
Brinda MonianKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
Duncan M MorganKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3253-1362
Naveen K MehtaKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
Bert RuiterCenter for Immunology & Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.
Wayne G ShrefflerCenter for Immunology & Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.
Alex K ShalekKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA. shalek@mit.edu.ORCID http://orcid.org/0000-0001-5670-8778
J Christopher LoveKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA. clove@mit.edu.ORCID http://orcid.org/0000-0003-0921-3144

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Paula T Hammond · 1985 to 2026
$93.9M
Role of Negative Costimulation in Regulation of AutoimmunityP01AI039671 · NIAID · YALE UNIVERSITY · PI David A. Hafler · 1996 to 2026
$51.7M
Systems investigation of vaccine responses in B cell depleted autoimmune patientsU19AI089992 · NIAID · YALE UNIVERSITY · PI David A. Hafler, RUTH R MONTGOMERY · 2010 to 2026
$50.4M
TCR recognition of MHC class II peptide compexes in multiple sclerosisP01AI045757 · NIAID · DANA-FARBER CANCER INSTITUTE · PI KUCHROO, VIJAY K., LOVE, JOHN CHRISTOPHER · 1999 to 2017
$22.8M
Center for Cell CircuitsRM1HG006193 · NHGRI · BROAD INSTITUTE, INC. · PI BLAINEY, PAUL CLARK, HACOHEN, NIR · 2016 to 2020
$14.9M
Novel Biologic Therapies for GVHDR01HL095791 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI KEAN, LESLIE S · 2010 to 2025
$13.3M
Tetramer CoreU19AI095261 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI XAVIER, RAMNIK J · 2011 to 2015
$10.8M
Quantitative and functional characterization of therapeutic resistance in cancerU54CA217377 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MANALIS, SCOTT R · 2017 to 2021
$10.2M
A systems biology approach to fingerprint HIV immune defense in Elite ControllersR01HL134539 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI YU, XU · 2016 to 2019
$3.3M
T cells in HCV/HIV co-infectionR01DA046277 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LAUER, GEORG MICHAEL · 2018 to 2022
$3.2M
"Bottom - Up" Profiling of Interacting Cellular SystemsDP2GM119419 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SHALEK, ALEX K · 2015 to 2015
$2.3M
An integrated multiplexed genomic assay for low input clinical samples1U24AI118672 · NIAID · BROAD INSTITUTE, INC. · PI SHALEK, ALEX K · 2015 to 2019
$2.0M
NCI NIH HHS P30 CA014051NCI NIH HHS R33 CA202820NCI NIH HHS U54 CA217377NHGRI NIH HHS RM1 HG006193NHLBI NIH HHS R01 HL095791NHLBI NIH HHS R01 HL134539NHLBI NIH HHS R56 HL126554NIAID NIH HHS P01 AI039671NIAID NIH HHS P01 AI045757NIAID NIH HHS R01 AI138546NIAID NIH HHS U19 AI089992NIAID NIH HHS U19 AI095261NIAID NIH HHS U24 AI118672NIDA NIH HHS R01 DA046277NIGMS NIH HHS DP2 GM119419
6 · The paper itself

Abstract

High-throughput 3' single-cell RNA-sequencing (scRNA-seq) allows cost-effective, detailed characterization of individual immune cells from tissues. Current techniques, however, are limited in their ability to elucidate essential immune cell features, including variable sequences of T cell antigen receptors (TCRs) that confer antigen specificity. Here, we present a strategy that enables simultaneous analysis of TCR sequences and corresponding full transcriptomes from 3'-barcoded scRNA-seq samples. This approach is compatible with common 3' scRNA-seq methods, and adaptable to processed samples post hoc. We applied the technique to identify transcriptional signatures associated with T cells sharing common TCRs from immunized mice and from patients with food allergy. We observed preferential phenotypes among subsets of expanded clonotypes, including type 2 helper CD4

Indexed as

2S Albumins, PlantAnimalsAntigens, PlantCD8-Positive T-LymphocytesCells, CulturedComplementarity Determining RegionsFemaleHigh-Throughput Nucleotide SequencingHumansImmunizationImmunoglobulin EMaleMiceMice, Inbred C57BLMice, TransgenicPapillomavirus E7 Proteins2S Albumins, PlantAntigens, PlantAra h 2 allergen, Arachis hypogaeaComplementarity Determining RegionsImmunoglobulin Eoncogene protein E7, Human papillomavirus type 16Papillomavirus E7 ProteinsReceptors, Antigen, T-Cell, alpha-beta

Identifiers

PMID31745340
PMCPMC7528220

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.